<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924650</url>
  </required_header>
  <id_info>
    <org_study_id>A6631040</org_study_id>
    <nct_id>NCT01924650</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Three Different Particle Sizes of PH-797804</brief_title>
  <official_title>A Randomized, Open Label, Single Dose, 6 Treatment, 4-way Crossover Study in Healthy Subjects to Assess the Pharmacokinetics of Three Different Particle Sizes of PH-797804 Tablet With and Without the Solubilizing Agent Sodium Lauryl Sulphate (SLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of varying particle size on the
      pharmacokinetics of PH-797804
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Time 72 hours (AUC72)</measure>
    <time_frame>0,2,3,4,5,6,8,12,24,48,72 hours post-dose</time_frame>
    <description>Area under the plasma concentration time-curve from zero to 72 hours (AUC72)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0,2,3,4,5,6,8,12,24,48,72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0,2,3,4,5,6,8,12,24,48,72 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PH-797804 PARTICLE SIZE 9-11UM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH-797804 PARTICLE SIZE 9-11UM WITH SLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH-797804 PARTICLE SIZE &lt;= 20UM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH-797804 PARTICLE SIZE &lt;= 20UM WITH SLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH-797804 PARTICLE SIZE &lt;= 5UM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH-797804 PARTICLE SIZE &lt;= 5UM WITH SLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804</intervention_name>
    <description>Tablet, 6 mg, single dose</description>
    <arm_group_label>PH-797804 PARTICLE SIZE 9-11UM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804</intervention_name>
    <description>Tablet, 6 mg, single dose</description>
    <arm_group_label>PH-797804 PARTICLE SIZE 9-11UM WITH SLS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804</intervention_name>
    <description>Tablet, 6 mg, single dose</description>
    <arm_group_label>PH-797804 PARTICLE SIZE &lt;= 20UM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804</intervention_name>
    <description>Tablet, 6 mg, single dose</description>
    <arm_group_label>PH-797804 PARTICLE SIZE &lt;= 20UM WITH SLS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804</intervention_name>
    <description>Tablet, 6 mg, single dose</description>
    <arm_group_label>PH-797804 PARTICLE SIZE &lt;= 5UM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804</intervention_name>
    <description>Tablet, 6 mg, single dose</description>
    <arm_group_label>PH-797804 PARTICLE SIZE &lt;= 5UM WITH SLS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects and/or healthy female subjects of non-child bearing potential
             between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically
             relevant abnormalities identified by a detailed medical history, full physical
             examination, including blood pressure and pulse rate measurements, 12-lead ECG and
             clinical laboratory tests.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt; 50 kg (110
             lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  A positive urine drug screen.

          -  History of regular alcohol consumption exceeding 14 drinks/week for males.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6631040&amp;StudyName=A%20Pharmacokinetic%20Study%20of%20Three%20Different%20Particle%20Sizes%20of%20PH-797804</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2013</study_first_submitted>
  <study_first_submitted_qc>August 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <last_update_submitted>December 19, 2013</last_update_submitted>
  <last_update_submitted_qc>December 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

